Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee A Hebert

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Journal of the American Society of Nephrology : JASN|August 13, 2016
BP Control and Long-Term Risk of ESRD and MortalityElaine Ku, Jennifer Gassman, Lawrence J Appel, et al.
American Journal of Human Genetics|May 16, 2007
Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European AmericansYan Yang, Erwin K Chung, Yee Ling Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosusHui Wu, Susan A Boackle, Punchong Hanvivadhanakul, et al.
The New England Journal of Medicine|September 8, 2010
Intensive blood-pressure control in hypertensive chronic kidney diseaseLawrence J Appel, Jackson T Wright, Tom Greene, et al.
Nephron|June 20, 2015
A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)Fernando C Fervenza, Pietro A Canetta, Sean J Barbour, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 8, 2014
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1Barry I Freedman, Carl D Langefeld, Kelly K Andringa, et al.
The New England Journal of Medicine|July 4, 2019
Rituximab or Cyclosporine in the Treatment of Membranous NephropathyFernando C Fervenza, Gerald B Appel, Sean J Barbour, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Journal of the American Society of Nephrology : JASN|August 13, 2016
BP Control and Long-Term Risk of ESRD and MortalityElaine Ku, Jennifer Gassman, Lawrence J Appel, et al.
American Journal of Human Genetics|May 16, 2007
Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European AmericansYan Yang, Erwin K Chung, Yee Ling Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2007
Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosusHui Wu, Susan A Boackle, Punchong Hanvivadhanakul, et al.
The New England Journal of Medicine|September 8, 2010
Intensive blood-pressure control in hypertensive chronic kidney diseaseLawrence J Appel, Jackson T Wright, Tom Greene, et al.
Nephron|June 20, 2015
A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR)Fernando C Fervenza, Pietro A Canetta, Sean J Barbour, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 8, 2014
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1Barry I Freedman, Carl D Langefeld, Kelly K Andringa, et al.
The New England Journal of Medicine|July 4, 2019
Rituximab or Cyclosporine in the Treatment of Membranous NephropathyFernando C Fervenza, Gerald B Appel, Sean J Barbour, et al.
Pageof 8